Your browser doesn't support javascript.
loading
Impact of the FreeStyle Libre 2® System on Glycaemic Outcomes in Patients with Type 1 Diabetes-Preliminary Study.
Rutkowska, Katarzyna; Los-Stegienta, Agnieszka; Baginski, Michal; Zieba, Ewa; Baran, Adrianna; Zurawska-Klis, Monika; Kosinski, Marcin; Cypryk, Katarzyna.
Afiliação
  • Rutkowska K; Department of Internal Diseases and Diabetology, Medical University of Lodz, 92-213 Lodz, Poland.
  • Los-Stegienta A; Department of Internal Diseases and Diabetology, Medical University of Lodz, 92-213 Lodz, Poland.
  • Baginski M; Faculty of Medicine, Medical University of Lodz, 90-419 Lodz, Poland.
  • Zieba E; Faculty of Medicine, Medical University of Lodz, 90-419 Lodz, Poland.
  • Baran A; Faculty of Medicine, Medical University of Lodz, 90-419 Lodz, Poland.
  • Zurawska-Klis M; Department of Internal Diseases and Diabetology, Medical University of Lodz, 92-213 Lodz, Poland.
  • Kosinski M; Department of Internal Diseases and Diabetology, Medical University of Lodz, 92-213 Lodz, Poland.
  • Cypryk K; Department of Internal Diseases and Diabetology, Medical University of Lodz, 92-213 Lodz, Poland.
Diagnostics (Basel) ; 14(16)2024 Aug 15.
Article em En | MEDLINE | ID: mdl-39202265
ABSTRACT
We aimed to evaluate glycaemic control in patients with type 1 diabetes during the first three months of use of the flash glucose monitoring (FGM) system.

METHODS:

We conducted a study of a cohort of 81 people with type 1 diabetes mellitus who used the FreeStyle Libre 2 (FSL2) sensor continuously for 3 months. Patients had not used a CGM before. The effectiveness of using the FSL2 system was assessed using AGP reports at two time points (3-4 weeks and 11-12 weeks of system use).

RESULTS:

Eight weeks after using FSL2, compared with results from 3-4 weeks of use, there were no differences in the glucose management indicator, time spent in range, above range and below range, or glucose variability. In the first month of FGM use, patients scanned the sensor significantly more often than in the following two months (p = 0.021). No significant differences were found in the change of the evaluated parameters when comparing patients by duration of diabetes and treatment method.

CONCLUSIONS:

Short-term use of FSL2 promotes a significant reduction in GMI in patients with more time spent in hyperglycaemia (especially > 250 mg/dL). In this short period of use, no other changes in glycaemic control parameters are observed.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Polônia País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Polônia País de publicação: Suíça